Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ZVRAthis companyZevra Therapeutics, Inc.	$11.85	6.4×	3.2×	4.65×	5.03×	-449.8%	84.5%	-4.0%	78.2%	53.8%	-1.7%	-0.5%	0.41×	0.01×	-0.53×	5.68×	0.0%	6	4.53	4	A-
ANROAlto Neuroscience, Inc.	$28.37	-8.13×	3.4×	0×	-5.68×	-73.1%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-10.1%	0.03×	2.86×	-26.88×	15.69×	0.0%	2	13.38	2	C+
MPLTMapLight Therapeutics, Inc.	$7.28	-4.8×	1.69×	0×	-4.56×	-86.3%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-17.9%	0.01×	0.25×	0×	20.01×	0.0%	2	5.7	2	C
NBIXNeurocrine Biosciences, Inc.	$166.72	29.49×	4.34×	4.93×	20.72×	140.9%	98.2%	21.6%	16.7%	14.7%	10.8%	5.3%	0.13×	-0.45×	0×	3.39×	0.0%	5	6.69	4	A
NMRANeumora Therapeutics, Inc. Common Stock	$0.51	-1.23×	2.82×	0×	-0.47×	121.4%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.15	2	C+
PRAXPraxis Precision Medicines, Inc.	$303.06	-21.86×	7.55×	0×	-20.7×	-94.6%	0.0%	0.0%	0.0%	-34.5%	-37.1%	-3.8%	0×	1.18×	0×	10.22×	0.0%	2	96.13	2	C
Peer median	—	-4.8×	3.4×	0×	-4.56×	-73.1%	0.0%	0.0%	0.0%	-35.2%	-37.1%	-10.1%	0.01×	0.78×	0×	10.22×	0.0%	2	6.69	2	—